GB2465677A — Compositions containing satiogens and methods of use

USPTO Abstract

A pharmaceutical composition comprising (i) an enteroendocrine peptide secretion enhancing agent and (ii) an absorption inhibitor of said enhancing agent and (iii) a pharmaceutically acceptable carrier, wherein (i) is preferably a bile acid, a bile salt, a bile acid mimic, a bile salt mimic or a combination thereof and (ii) is preferably a mucoadhesive agent, more preferably a methylcellulose, a polycarbophil, a polyvinylpyrrolidone (PVP) or a carboxymethylcellulose. The said composition is of use in the treatment of a metabolic disorder such as obesity, diabetes, appetite, weight gain, glucose intolerance and insulin resistance.